Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

NCT00168363 ↗

Phase 3 Completed 207 enrolled Allergan

RandomizedParallel-groupDouble-blindTreatment

Summary

This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension

Timeline

Start: 2005-01
Primary completion: 2006-08
Completion: 2006-08

Outcome

Met primary endpoint

paper Brimonidine-purite 0.1% provided IOP-lowering that was non-inferior to brimonidine-purite 0.15% at each of the 12 follow-up timepoints PMID 18534052 ↗

Publications

Cantor LB, Safyan E, Liu CC, Batoosingh AL. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Curr Med Res Opin. 2008 Jul;24(7):2035-43. doi: 10.1185/03007990802199287. Epub 2008 Jun 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brimonidine	Unknown	0.1 %	—
Subject	Brimonidine	Unknown	0.15 %	—